Normal insulin secretion in humans is mainly regulated by glucose, but additional factors including other nutrients, hormones, and neural input play an important role. In the basal state, insulin is released in a rapid pulsatile manner, with pulses occurring every 6–10 min. These pulses are superimposed on an oscillatory pattern of 11–15 oscillations per 24 h. Dynamic insulin release also occurs in response to stimuli. The insulin response to intravenous glucose has been shown to have two distinct phases: an early first phase response lasting for 10 min, and a slower longer second phase response lasting as long as the glucose level is elevated. Preexistent elevations in the plasma glucose level are able to increase the insulin response to a subsequent glucose stimulus, an effect called priming. Glucose is also capable of potentiating the insulin response to non‐glucose secretagogues such as amino acids, peptides, and sulfonylureas. Non‐glucose factors that affect insulin secretion include amino acids, free fatty acids, medications, and the response to stress. Neural inputs regulate islet secretory function through both the sympathetic and parasympathetic nervous systems. The gastrointestinal peptides glucagon‐like peptide 1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP), released from the intestine during oral intake, have been found to play a significant role in augmenting insulin release, an effect known as the incretin effect. When assessing the effect of all these different secretagogues on β‐cell function, it is important to take into account the prevailing insulin sensitivity, as variations in insulin sensitivity lead to compensatory changes in insulin release. Understanding the dynamics and complex regulation of normal insulin secretion in humans provides the basis for understanding the consequences of β‐cell dysfunction observed in diabetes.